Savara Inc (NASDAQ:SVRA) CEO Matthew Pauls purchased 28,700 shares of the company’s stock in a transaction that occurred on Monday, February 22nd. The shares were purchased at an average price of $1.74 per share, for a total transaction of $49,938.00.
Shares of SVRA stock traded up $0.20 on Tuesday, reaching $1.93. The stock had a trading volume of 44,824 shares, compared to its average volume of 481,044. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.61 and a current ratio of 12.61. Savara Inc has a 1 year low of $1.00 and a 1 year high of $3.17. The stock has a market cap of $104.49 million, a P/E ratio of -1.30 and a beta of 1.18. The company has a 50 day simple moving average of $1.61 and a 200 day simple moving average of $1.38.
Hedge funds have recently bought and sold shares of the business. Sofinnova Investments Inc. bought a new stake in shares of Savara during the 3rd quarter valued at about $409,000. Bank of America Corp DE raised its position in Savara by 48.3% in the second quarter. Bank of America Corp DE now owns 20,603 shares of the company’s stock worth $51,000 after acquiring an additional 6,708 shares during the period. Metropolitan Life Insurance Co NY bought a new stake in shares of Savara during the 1st quarter valued at $83,000. JPMorgan Chase & Co. increased its stake in shares of Savara by 698.8% in the 4th quarter. JPMorgan Chase & Co. now owns 143,729 shares of the company’s stock worth $166,000 after purchasing an additional 125,737 shares in the last quarter. Finally, Rhumbline Advisers increased its holdings in Savara by 16.7% in the 4th quarter. Rhumbline Advisers now owns 70,848 shares of the company’s stock worth $81,000 after acquiring an additional 10,135 shares in the last quarter. 40.66% of the stock is currently owned by institutional investors.
Savara Company Profile
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Recommended Story: Understanding Stock Ratings
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.